1107 related articles for article (PubMed ID: 15632206)
1. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Miller JS; Soignier Y; Panoskaltsis-Mortari A; McNearney SA; Yun GH; Fautsch SK; McKenna D; Le C; Defor TE; Burns LJ; Orchard PJ; Blazar BR; Wagner JE; Slungaard A; Weisdorf DJ; Okazaki IJ; McGlave PB
Blood; 2005 Apr; 105(8):3051-7. PubMed ID: 15632206
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
6. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
7. Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.
Williams RL; Cooley S; Bachanova V; Blazar BR; Weisdorf DJ; Miller JS; Verneris MR
Biol Blood Marrow Transplant; 2018 Mar; 24(3):618-622. PubMed ID: 29197679
[TBL] [Abstract][Full Text] [Related]
8. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
[TBL] [Abstract][Full Text] [Related]
9. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
10. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
11. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
13. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
14. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
15. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
16. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic natural killer cells for refractory lymphoma.
Bachanova V; Burns LJ; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lindgren BR; Cooley S; Weisdorf D; Miller JS
Cancer Immunol Immunother; 2010 Nov; 59(11):1739-44. PubMed ID: 20680271
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
